Grants and Contributions:
Title:
COVID-19 Response (TI): antivrial & Inflammation Controlling Therapeutic Drug Clinical Evaluation
Agreement Number:
958708
Agreement Value:
$10,000,000.00
Agreement Date:
Oct 1, 2020 - Mar 31, 2023
Description:
Clinical development of LAU-7b antiviral and inflammation-controlling therapy for COVID-19 infection.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Montreal, Quebec, CA H3A 2R7
Reference Number:
172-2020-2021-Q3-958708
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
835517442
Recipient Type:
For-profit organization
Additional Information:
This agreement has been amended 1 time(s). The end date of this agreements has been modified by 90 days.
Amendment Date
Nov 28, 2022
Recipient's Operating Name:
Laurent Thérapeutiques
Recipient's Legal Name:
Laurent Pharmaceuticals Inc.
Federal Riding Name:
Ville-Marie--Le Sud-Ouest--Île-des-Soeurs
Federal Riding Number:
24077
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710
Amendments: